We are happy to inform our readers that we have commenced dosing women in the fourth cohort of our ongoing Phase 1 clinical trial of COTI-2 intended for the treatment of gynecological cancers. The objective of the fourth cohort is to continue to evaluate the safety and tolerability of COTI-2.
Independent Dose Escalation Committee recommends continuing the study at an increased dosage
“We are pleased to report that the first two patients in cohort 4 have begun receiving COTI‐2 at a dosage level of 1.7 mg/kg, an increase from the 1.0 mg/kg level of cohort 3. We are further pleased to report that there were no significant adverse events attributed to treatment in any of the cohort 3 patients. Preliminary clinical data is consistent with the low toxicity profile observed during preclinical studies. Accordingly, the independent Dose Escalation Committee granted a favourable opinion to move ahead with the fourth cohort of patients. We are pleased with the Committee’s recommendation and trial advancement to date.” - Alison Silva, President and CEO.